In this week’s news, Quotient Sciences completes £6M expansion, Recipharm strengthens pre-filled syringes and cartridge offerings, and more.
Quotient Sciences completes £6M expansion including a state-of-the-art drug substance manufacturing capability to support candidate selection through to clinical development.The facility has multipurpose capacity of up to 15 GMP reactor streams with reactor volumes ranging from 5 liters up to 150 liters and tactical deployment of batch or continuous flow chemistry technologies to optimize drug substance manufacturing processes.
Recipharm strengthens pre-filled syringes and cartridge offerings with new investment. The new line can support small-volume projects as well as large ones and is expected to be ready for technical trials by April 2022, with the first GMP batch to run in May next year.
Terumo launch ready-to-fill polymer syringe.The PLAJEX 2.25 mL with Tapered Needle is specifically designed to meet the demands of the Biotech market, making it suitable for complex drug applications, such as high viscosity biotech medications. The syringe enables pharmaceutical customers to offer a safe, easy-to-use, and effective treatment option that maximises patient convenience.
Big Pharma companies carry great responsibility for patients and the environment, and, like so many other industries, pharma is thinking more and more about its impact on the world and its climate. Environmental sustainability has become an increasingly common theme within the pharma industry, as companies work to establish a responsible corporate image before the public.
What happens when manufacturing plants are moving targets? When quality systems are at once more centralized and dispersed? When plant operators are health care workers? FDA seeks answers on distributed manufacturing.
Also in the news
A new country-wide marketing campaign urging millions of eligible people to get their flu and COVID-19 booster vaccines to top up their immunity launched on Monday (24 October), as almost 10 million people in England have already received their boosters.
Cingulate Inc., has executed a Master Services Agreement (MSA) with Societal CDMO, Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development.
FUJIFILM Diosynth Biotechnologies and RoosterBio announce collaboration to enable GMP manufacturing of cell and exosome therapies
Scorpion Biological Services, a fully integrated CRO and CDMO focused on the development of biologic drugs, hosted the grand opening of its new, state-of-the-art San Antonio facility.
27th June, 2022
Competition is more aggressive than ever in our space and a key to differentiation...Read more
18th January, 2021
Over the past six months, our Founder and Global President Raman Sehgal has conducted...Read more